A gene hypermethylation profile of human cancer

Cancer Research

Volumn 61, Issue 8, 2001, Pages 3225-3229

  Esteller, Manel ^a,b   Corn, Paul G ^a   Baylin, Stephen B ^a   Herman, James G ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Structural Biology and Biocomputing Programme   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; BRCA1 PROTEIN; DEATH ASSOCIATED PROTEIN KINASE; GENE PRODUCT; GLUTATHIONE TRANSFERASE P1; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN MLH1; PROTEIN P14; PROTEIN P15; PROTEIN P16; PROTEIN P73; TISSUE INHIBITOR OF METALLOPROTEINASE 3; UNCLASSIFIED DRUG; UVOMORULIN;

ARTICLE; CANCER CLASSIFICATION; CANCER GENETICS; DNA REPAIR; GENE ISOLATION; GENE SILENCING; GENETIC ANALYSIS; GENETIC MARKER; HUMAN; HUMAN TISSUE; HYPERMETHYLATION; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN METHYLATION; TISSUE SPECIFICITY; TUMOR SUPPRESSOR GENE;

DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, TUMOR SUPPRESSOR; GENETIC MARKERS; HUMANS; NEOPLASMS; PROMOTER REGIONS (GENETICS);

EID: 0035870248     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Serial analysis of gene expression
2. Systematic variation in gene expression patterns in human cancer cell lines
3. Cancer epigenetics comes of age
4. DNA hypermethylation in tumorigenesis: Epigenetics joins genetics
5. Aberrant CpG-island methylation has nonrandom and tumour-type-specific patterns
6. Methylation-induced repression-belts, braces, and chromatin
7. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers
8. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers
9. Methylation of the 5′ CpG island of the p16/CDKN2 tumor-suppressor gene in normal and transformed human tissues correlates with gene silencing
10. Progressive increases in de novo methylation of CpG islands in bladder cancer
11. In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis
12. Low frequency of p16/CDKN2A methylation in sporadic melanoma: Comparative approaches for methylation analysis of primary tumors
13. Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation
14. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia
15. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis
16. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from nonsmall cell cancer patients
17. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients
18. INK4a methylation and p53 mutational status
19. Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer
20. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia
21. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis
22. A specific CpG methylation pattern of the MGMT promoter region associated with reduced MGMT expression in primary colorectal cancers
23. Hypermethylation of the APC (adenomatous polyposis coli) gene promoter region in human colorectal carcinoma
24. ARF gene in gastric cancer
25. DAP-kinase loss of expression in various carcinoma and B-cell lymphoma cell lines: Possible implications for role as tumor suppressor gene
26. GSTP1 CpG island DNA hypermethylation in hepatocellular carcinomas
27. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors
28. Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer
29. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines
30. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma
31. MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas
32. Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability
33. Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5′ CpG island methylation
34. Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation
35. INK4B
36. Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia
37. Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: Potential prognostic implications
38. Hypermethylation of multiple genes in pancreatic adenocarcinoma
39. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma
40. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype
41. CpG island methylator phenotype in colorectal cancer
42. Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia
43. The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53
44. INK4a is an early event in lung cancer and a potential biomarker for early diagnosis
45. hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis
46. Microsatellite instability in inflammatory bowel disease-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH1
47. Identification and characterization of differentially methylated regions of genomic DNA by methylation-sensitive arbitrarily primed PCR
48. Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification
49. Restriction landmark genomic scanning method and its various applications
50. Methylation profiling of CpG islands in human breast cancer cells
51. The gene for a novel transmembrane protein containing epidermal growth factor and follistatin domains is frequently hypermethylated in human tumor cells
52. TMS1, a novel proapoptotic caspase recruitment domain protein, is a target of methylation-induced gene silencing in human breast cancers
53. Predicting lung cancer by detecting aberrant promoter methylation in sputum
54. Inactivation of the DNA repair gene MGMT and the clinical response of gliomas to alkylating agents
55. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer
56. Glutathione-associated enzymes in anticancer drug resistance
57. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I nonsmall-cell lung cancer